Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study

H Tilly; F Morschhauser; LH Sehn; JW Friedberg; M Trneny; JP Sharman; C Herbaux; JM Burke; M Matasar; S Rai; K Izutsu; N Mehta-Shah; L Oberic; A Chauchet; W Jurczak; YQ Song; Richard Greil; L Mykhalska; J Miguel; B Burgues; MC Cheung; A Pinto; HJ Shin; G Hapgood; E Munhoz; P Abrisqueta; JP Gau; J Hirata; YW Jiang; M Yan; C Lee; C Flowers; G Salles; G Collins

Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study

H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trneny, JP Sharman, C Herbaux, JM Burke, M Matasar, S Rai, K Izutsu, N Mehta-Shah, L Oberic, A Chauchet, W Jurczak, YQ Song, Richard Greil, L Mykhalska, J Miguel, B BurguesMC Cheung, A Pinto, HJ Shin, G Hapgood, E Munhoz, P Abrisqueta, JP Gau, J Hirata, YW Jiang, M Yan, C Lee, C Flowers, G Salles, G Collins

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	14-16
Journal	BRITISH JOURNAL OF HAEMATOLOGY
Volume	197
Publication status	Published - 2022

Cite this

Tilly, H., Morschhauser, F., Sehn, LH., Friedberg, JW., Trneny, M., Sharman, JP., Herbaux, C., Burke, JM., Matasar, M., Rai, S., Izutsu, K., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, YQ., Greil, R., Mykhalska, L., Miguel, J., ... Collins, G. (2022). Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study. BRITISH JOURNAL OF HAEMATOLOGY , 197, 14-16.

Tilly, H ; Morschhauser, F ; Sehn, LH et al. / Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study. In: BRITISH JOURNAL OF HAEMATOLOGY 2022 ; Vol. 197. pp. 14-16.

@article{ea15df9a6a4a45d998756f9170395a85,

title = "Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study",

author = "H Tilly and F Morschhauser and LH Sehn and JW Friedberg and M Trneny and JP Sharman and C Herbaux and JM Burke and M Matasar and S Rai and K Izutsu and N Mehta-Shah and L Oberic and A Chauchet and W Jurczak and YQ Song and Richard Greil and L Mykhalska and J Miguel and B Burgues and MC Cheung and A Pinto and HJ Shin and G Hapgood and E Munhoz and P Abrisqueta and JP Gau and J Hirata and YW Jiang and M Yan and C Lee and C Flowers and G Salles and G Collins",

year = "2022",

language = "English",

volume = "197",

pages = "14--16",

journal = "BRITISH JOURNAL OF HAEMATOLOGY ",

issn = "0007-1048",

}

Tilly, H, Morschhauser, F, Sehn, LH, Friedberg, JW, Trneny, M, Sharman, JP, Herbaux, C, Burke, JM, Matasar, M, Rai, S, Izutsu, K, Mehta-Shah, N, Oberic, L, Chauchet, A, Jurczak, W, Song, YQ, Greil, R, Mykhalska, L, Miguel, J, Burgues, B, Cheung, MC, Pinto, A, Shin, HJ, Hapgood, G, Munhoz, E, Abrisqueta, P, Gau, JP, Hirata, J, Jiang, YW, Yan, M, Lee, C, Flowers, C, Salles, G & Collins, G 2022, 'Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study', BRITISH JOURNAL OF HAEMATOLOGY , vol. 197, pp. 14-16.

Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study. / Tilly, H; Morschhauser, F; Sehn, LH et al.
In: BRITISH JOURNAL OF HAEMATOLOGY , Vol. 197, 2022, p. 14-16.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study

AU - Tilly, H

AU - Morschhauser, F

AU - Sehn, LH

AU - Friedberg, JW

AU - Trneny, M

AU - Sharman, JP

AU - Herbaux, C

AU - Burke, JM

AU - Matasar, M

AU - Rai, S

AU - Izutsu, K

AU - Mehta-Shah, N

AU - Oberic, L

AU - Chauchet, A

AU - Jurczak, W

AU - Song, YQ

AU - Greil, Richard

AU - Mykhalska, L

AU - Miguel, J

AU - Burgues, B

AU - Cheung, MC

AU - Pinto, A

AU - Shin, HJ

AU - Hapgood, G

AU - Munhoz, E

AU - Abrisqueta, P

AU - Gau, JP

AU - Hirata, J

AU - Jiang, YW

AU - Yan, M

AU - Lee, C

AU - Flowers, C

AU - Salles, G

AU - Collins, G

PY - 2022

Y1 - 2022

M3 - Abstract (Journal)

SN - 0007-1048

VL - 197

SP - 14

EP - 16

JO - BRITISH JOURNAL OF HAEMATOLOGY

JF - BRITISH JOURNAL OF HAEMATOLOGY

ER -

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP et al. Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study. BRITISH JOURNAL OF HAEMATOLOGY . 2022;197:14-16.